Literature DB >> 26461464

Treatment Considerations of Lung Involvement in Rheumatologic Disease.

Alejandro Robles-Perez1, Maria Molina-Molina.   

Abstract

Lung involvement in rheumatologic diseases has a broad spectrum of clinical and radiological presentations, from acute and inflammatory predominance to chronic and fibrotic lung disorders. Therapy has to be guided by the type of rheumatologic disease, the kind of lung involvement and the risk associated with the clinical state of the patient and prognostic factors. Although several therapeutic approaches have been used, the best treatment is still not certain; clinical trials are mandatory, which would require a better knowledge of the pulmonary pathogenesis of immunologic diseases. The following review is focused on the therapeutic options for those rheumatologic disorders that could present as a predominant interstitial lung disease which may confer a bad or life-threatening prognosis.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26461464     DOI: 10.1159/000441238

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  5 in total

1.  Cyclophosphamide pulse therapy as treatment for severe interstitial lung diseases.

Authors:  Arik Bernard Schulze; Georg Evers; Andreas Kümmel; Felix Rosenow; Jan Sackarnd; Jan Philipp Hering; Christoph Schülke; Jonas Andreas Engelbertz; Dennis Görlich; Peter J Barth; Georg Lenz; Heidemarie Becker; Michael Mohr; Lars Henning Schmidt
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 2.  Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges.

Authors:  Andrew McLean-Tooke; Irene Moore; Fiona Lake
Journal:  Clin Transl Immunology       Date:  2019-11-05

Review 3.  Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.

Authors:  Caterina Vacchi; Marco Sebastiani; Giulia Cassone; Stefania Cerri; Giovanni Della Casa; Carlo Salvarani; Andreina Manfredi
Journal:  J Clin Med       Date:  2020-02-03       Impact factor: 4.241

Review 4.  Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease.

Authors:  Caterina Vacchi; Andreina Manfredi; Giulia Cassone; Gian Luca Erre; Carlo Salvarani; Marco Sebastiani
Journal:  Drugs Context       Date:  2021-01-15

5.  Selection of glucocorticoid-sensitive patients in interstitial lung disease secondary to connective tissue diseases population by radiomics.

Authors:  Ding-Yun Feng; Yu-Qi Zhou; Yan-Fang Xing; Chuang-Feng Li; Qing Lv; Jie Dong; Jie Qin; Yue-Fei Guo; Nan Jiang; Chencui Huang; Hai-Tao Hu; Xing-Hua Guo; Jie Chen; Liang-Hong Yin; Tian-Tuo Zhang; Xing Li
Journal:  Ther Clin Risk Manag       Date:  2018-10-10       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.